Akoya Biosciences announced on February 5, 2025, its reagent product roadmap, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. These panels are slated for release at the end of Q1 and Q2 2025, respectively, building on the success of the Human IO60 and Mouse FFPE IO panels launched in November 2024.
The new neurobiology panels aim to address the critical need for comprehensive spatial insights in neuroscience research, enabling advancements in understanding neurodegenerative diseases, disease modeling, and therapeutic development. This expansion broadens Akoya's reach into new verticals beyond oncology and inflammatory disease.
The company stated that the rapid expansion of its PhenoCycler-Fusion content menu is a direct result of the efficiency and robustness of its fully operational Manufacturing Center of Excellence. This internal manufacturing capability supports the development of ready-to-use high-plex panels, designed to capture an expanding market segment and drive discoveries.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.